CMMB Chemomab Therapeutics Ltd. - American Depositary Shares
$1,92
Prezzo · Ago 19, 2026
Fondamentali al Mag 11, 2023
Intervallo 52 sett.
$1–$4
21% of range
Rating Analisti
BUY
8 analysts
Prezzo Obiettivo
$5
+160% upside
P/E (TTM)
—
ROE
—
Margine di Profitto Netto
—
CMMB Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$1.92
Capitalizzazione di Mercato
—
P/E (TTM)
—
EPS (TTM)
—
Ricavi (TTM)
—
Rendimento div.
—
ROE
—
D/E Debito/Patrimonio
—
Intervallo 52 sett.
$1 – $4
CMMB Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
—
EPS
—
2021-12-31
→
2022-12-31
Flusso di cassa libero
—
2019-12-31
→
2022-12-31
Margini
—
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
CMMB
Mediana dei peer
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
CMMB
Mediana dei peer
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
CMMB
Mediana dei peer
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
CMMB
Mediana dei peer
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
CMMB
Mediana dei peer
CMMB Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
8 analisti
- Acquisto forte 3 37,5%
- Compra 4 50,0%
- Mantieni 1 12,5%
- Vendi 0 0,0%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
1 analisti · 2026-08-13
Basso
$5.00
Alto
$5.00
Target mediano
$5.00
+160,4%
Target medio
$5.00
+160,4%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
-0.43%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 31 Marzo 2026 | $-0.24 | $-0.16 | -0.08% |
| 31 Dicembre 2025 | $-0.24 | $-0.32 | 0.08% |
| 31 Marzo 2025 | $-0.56 | $-0.04 | -0.52% |
| 31 Dicembre 2024 | $-0.64 | $-0.32 | -0.32% |
| 30 Settembre 2024 | $-0.80 | $-0.02 | -0.78% |
| 30 Giugno 2024 | $-1.04 | $-0.06 | -0.98% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| CMMB | — | — | — | — | — | — |
| PLRZ | — | — | — | — | — | — |
| PLUR | $39M | -1.4 | 309.8% | -1690.3% | 669.5% | 48.9% |
| NRSN | — | — | — | — | — | — |
| QNRX | $757M | — | — | — | -201.7% | — |
| EVGN | — | — | — | — | — | — |
| CLGN | — | — | — | — | — | — |
| GLMD | — | — | — | — | — | — |
| URGN | $1.13B | — | 21.4% | -139.8% | 154.4% | 88.7% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 11
| Metrica | Tendenza | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| R&D Expense | $17M | $6M | $5M | $13M | $8M | |
| SG&A Expense | $12M | $6M | $1M | $6M | $6M | |
| Operating Expenses | $29M | $12M | $6M | $23M | $13M | |
| Other Non-op | $353.0K | $-111.0K | · | · | · | |
| Pretax Income | $-28M | $-12M | $6M | $27M | $13M | |
| Income Tax | $-534.0K | $0 | · | $0 | $306.0K | |
| Net Income | $-28M | $-12M | $-6M | $-27M | $-14M | |
| EPS (Basic) | $0.12 | $0.06 | · | · | · | |
| EPS (Diluted) | $0.12 | $0.06 | · | · | · | |
| Shares (Basic) | 227,589,288 | 207,468,650 | · | · | · | |
| Shares (Diluted) | 227,589,288 | 207,468,650 | · | · | · |
Stato Patrimoniale 20
| Metrica | Tendenza | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $14M | $15M | $12M | $18M | $8M | |
| Receivables | · | · | · | $408.0K | $3M | |
| Prepaid Expense | $2M | $2M | $141.0K | $636.0K | · | |
| Current Assets | $42M | $63M | $12M | $18M | $11M | |
| PP&E (Net) | $367.0K | $357.0K | $152.0K | $158.0K | $385.0K | |
| PP&E (Gross) | $532.0K | $464.0K | $225.0K | · | · | |
| Accum. Depreciation | $165.0K | $107.0K | $73.0K | · | · | |
| Other Non-current Assets | · | · | $51.0K | $57.0K | · | |
| Total Assets | $43M | $64M | $12M | $20M | $13M | |
| Accrued Liabilities | $3M | $555.0K | $715.0K | $372.0K | $2M | |
| Current Liabilities | $7M | $3M | $1M | $4M | $3M | |
| Capital Leases | $91.0K | $237.0K | $358.0K | $725.0K | · | |
| Total Liabilities | $7M | $3M | $2M | $5M | $3M | |
| Common Stock | $0 | $0 | · | · | · | |
| Paid-in Capital | $101M | $98M | $34M | $119M | $87M | |
| Retained Earnings | $-64M | $-36M | $-24M | $-105M | $-78M | |
| Treasury Stock | $1M | $0 | · | · | · | |
| Stockholders' Equity | $36M | $61M | $11M | $12M | $10M | |
| Liabilities + Equity | $43M | $64M | $12M | $20M | $13M | |
| Shares Outstanding | 232,636,700 | 228,090,300 | 9,274,838 | 37,099,352 | 15,575,682 |
Flusso di cassa 11
| Metrica | Tendenza | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Stock-based Comp | $3M | $2M | $130.0K | $1M | $2M | |
| Restructuring | · | · | $749.0K | $3M | · | |
| Operating Cash Flow | $-20M | $-12M | $-5M | $-16M | $-14M | |
| CapEx | $68.0K | $239.0K | $38.0K | $95.0K | $213.0K | |
| Investing Cash Flow | $20M | $-45M | $-62.0K | $-95.0K | $-213.0K | |
| Stock Issued | · | · | $0 | $30M | $23M | |
| Net Stock Activity | · | · | $0 | $30M | · | |
| Financing Cash Flow | $-808.0K | $61M | $5M | $27M | $21M | |
| Net Change in Cash | $-2M | $4M | $-554.0K | $10M | $6M | |
| Taxes Paid | $5.0K | $0 | $84.0K | $161.0K | $244.0K | |
| Free Cash Flow | $-20M | $-13M | $-13M | $-17M | · |
Redditività 2
| Metrica | Tendenza | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| ROA | -51.5% | -32.5% | -89.5% | -166.8% | · | |
| ROE | -62.8% | -19.7% | -147.6% | -153.6% | · |
Liquidità e Solvibilità 2
| Metrica | Tendenza | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Current Ratio | 6.2 | 23.7 | 2.4 | 4.4 | · | |
| Quick Ratio | 2.0 | 5.7 | 2.1 | 4.4 | · |
Tassi di Crescita 1
| Metrica | Tendenza | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| EPS YoY | 101.7% | · | · | · | · |
Valutazione (TTM) 8
| Metrica | Tendenza | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Net Income TTM | $-28M | $-12M | $-6M | $-27M | · | |
| Market Cap | · | · | $4.11B | $3.32B | · | |
| P/E | 105.8 | 460.0 | · | · | · | |
| P/B | · | · | 1148.3 | 223.0 | · | |
| P / Tangible Book | · | · | 380.3 | · | · | |
| P / Cash Flow | · | · | -323.1 | -202.0 | · | |
| P / FCF | · | · | -322.3 | -200.8 | · | |
| Earnings Yield | 0.95% | 0.22% | · | · | · |
Conto Economico 10
| Metrica | Tendenza | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $7M | $6M | $5M | $3M | $3M | $2M | $1M | $1M | $1M | $1M | $1M | $847.0K | $2M | $1M | |
| SG&A Expense | $2M | $3M | $3M | $3M | $3M | $3M | $1M | $1M | $542.0K | $688.0K | $194.0K | $254.0K | $152.0K | $1M | |
| Operating Expenses | $9M | $9M | $8M | $6M | $5M | $5M | $3M | $3M | $2M | $2M | $1M | $1M | $2M | $6M | |
| Pretax Income | $-9M | $-8M | $-8M | $-7M | $-5M | $-5M | $-3M | $-3M | · | · | · | · | · | · | |
| Income Tax | $21.0K | $10.0K | $0 | $-544.0K | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Income | $-9M | $-8M | $-8M | $-6M | $-5M | $-5M | $-3M | $-3M | $-2M | $-2M | $-1M | $-1M | $-2M | $-6M | |
| EPS (Basic) | $0.04 | $0.04 | $0.04 | $0.03 | $0.02 | $0.02 | $0.01 | $0.01 | · | · | · | · | · | · | |
| EPS (Diluted) | $0.04 | $0.04 | $0.04 | $0.03 | $0.02 | $0.02 | $0.01 | $0.01 | · | · | · | · | · | · | |
| Shares (Basic) | 220,996,240 | -457,447,706 | 228,773,418 | 228,173,276 | 228,090,300 | 12,176,266 | 227,956,060 | 216,266,993 | · | · | · | · | · | · | |
| Shares (Diluted) | 220,996,240 | -457,447,706 | 228,773,418 | 228,173,276 | 228,090,300 | 12,176,266 | 227,956,060 | 216,266,993 | · | · | · | · | · | · |
Stato Patrimoniale 19
| Metrica | Tendenza | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $21M | $14M | $11M | $10M | $14M | $15M | $38M | $45M | $58M | $12M | $7M | $9M | $14M | $18M | |
| Prepaid Expense | $995.0K | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $320.0K | $141.0K | $620.0K | $848.0K | $542.0K | $636.0K | |
| Current Assets | $34M | $42M | $49M | $55M | $59M | $63M | $66M | $69M | $60M | $12M | $7M | $10M | $15M | $18M | |
| PP&E (Net) | $352.0K | $367.0K | $380.0K | $355.0K | $358.0K | $357.0K | $234.0K | $243.0K | $148.0K | $152.0K | $15.0K | $18.0K | $121.0K | $158.0K | |
| PP&E (Gross) | · | $532.0K | · | · | · | $464.0K | · | · | · | $225.0K | · | · | · | · | |
| Accum. Depreciation | · | $165.0K | · | · | · | $107.0K | · | · | · | $73.0K | · | · | · | · | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | · | · | $52.0K | $51.0K | $46.0K | $57.0K | |
| Total Assets | $35M | $43M | $50M | $56M | $61M | $64M | $67M | $71M | $60M | $12M | $8M | $10M | $15M | $20M | |
| Accrued Liabilities | $3M | $3M | $3M | $2M | $1M | $555.0K | $637.0K | $977.0K | $2M | $715.0K | $1M | $352.0K | $935.0K | $372.0K | |
| Current Liabilities | $7M | $7M | $5M | $4M | $4M | $3M | $2M | $2M | $5M | $1M | $2M | $2M | $3M | $4M | |
| Capital Leases | $62.0K | $91.0K | $118.0K | $148.0K | $203.0K | $237.0K | $298.0K | $320.0K | $328.0K | $358.0K | $63.0K | $108.0K | $152.0K | $725.0K | |
| Total Liabilities | $7M | $7M | $6M | $5M | $4M | $3M | $2M | $2M | $5M | $2M | $2M | $2M | $4M | $5M | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | · | · | $0 | · | $0 | · | · | · | |
| Paid-in Capital | $102M | $101M | $100M | $99M | $99M | $98M | $97M | $96M | $81M | $34M | $119M | $120M | $120M | $119M | |
| Retained Earnings | $-73M | $-64M | $-56M | $-47M | $-41M | $-36M | $-31M | $-28M | $-25M | $-24M | $-115M | $-112M | $-109M | $-105M | |
| Treasury Stock | $1M | $1M | · | · | · | $0 | · | · | · | · | · | · | · | · | |
| Stockholders' Equity | $28M | $36M | $45M | $52M | $57M | $61M | $66M | $68M | $55M | $11M | $5M | $8M | $12M | $15M | |
| Liabilities + Equity | $35M | $43M | $50M | $56M | $61M | $64M | $67M | $71M | $60M | $12M | $8M | $10M | $15M | $20M | |
| Shares Outstanding | 232,636,700 | · | 229,015,402 | 228,633,120 | 228,090,300 | · | 227,956,060 | 227,956,060 | 213,959,940 | · | 37,099,352 | 37,099,352 | 37,099,352 | 37,099,352 |
Flusso di cassa 11
| Metrica | Tendenza | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $484.0K | $740.0K | $836.0K | $761.0K | $874.0K | $1M | $441.0K | $527.0K | $43.0K | $33.0K | $-167.0K | $-112.0K | $46.0K | $89.0K | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $79.0K | $0 | $670.0K | · | |
| Operating Cash Flow | $-7M | $-6M | $-5M | $-6M | $-4M | $-3M | $-3M | $-6M | $-1M | $-2M | $5M | $750.0K | $-2M | $-6M | |
| CapEx | $1.0K | $1.0K | $42.0K | $11.0K | $14.0K | $134.0K | $0 | $102.0K | $3.0K | $1.0K | $3.0K | $-17.0K | $10.0K | $-251.0K | |
| Investing Cash Flow | $14M | $9M | $6M | $2M | $2M | $-20M | $-5M | $-21M | $-2.0K | $-3.0K | $-144.0K | $-5.0K | $-10.0K | $251.0K | |
| Stock Issued | · | · | · | · | · | · | · | · | $45M | · | $0 | $0 | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | · | $45M | · | · | · | $0 | · | |
| Financing Cash Flow | $0 | $-869.0K | $39.0K | $22.0K | $0 | $-81.0K | $-72.0K | $13M | $48M | $563.0K | $4M | $4M | $500.0K | $0 | |
| Net Change in Cash | $7M | $3M | $858.0K | $-4M | $-1M | $-23M | $-8M | $-13M | $47M | $-995.0K | $9M | $4M | $-1M | $-6M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $-444.0K | |
| Free Cash Flow | $-7M | · | · | · | $-4M | · | · | · | $-1M | · | · | · | $-4M | · |
Redditività 2
| Metrica | Tendenza | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -18.2% | · | -13.7% | -9.8% | -8.4% | · | -7.9% | -6.9% | -4.5% | · | -63.7% | -69.5% | -46.6% | · | |
| ROE | -20.5% | · | -14.7% | -10.3% | -9.1% | · | -8.4% | -7.3% | -5.1% | · | -91.5% | -85.4% | -61.2% | · |
Liquidità e Solvibilità 2
| Metrica | Tendenza | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.8 | · | 8.9 | 12.5 | 16.9 | · | 40.4 | 31.9 | 12.9 | · | 3.2 | 5.5 | 4.2 | · | |
| Quick Ratio | 3.0 | · | 2.0 | 2.2 | 3.9 | · | 23.2 | 21.0 | 12.6 | · | 3.0 | 5.0 | 4.0 | · |
Valutazione (TTM) 8
| Metrica | Tendenza | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-28M | · | $-22M | $-17M | $-13M | · | $-9M | $-7M | $-6M | · | $-11M | $-14M | $-23M | · | |
| Market Cap | $1.48B | · | $2.28B | $3.38B | $4.38B | · | $10.10B | $17.34B | $24.57B | · | $2.71B | $3.25B | $1.87B | · | |
| P/E | 51.3 | · | 102.7 | 197.3 | · | · | · | · | · | · | · | · | · | · | |
| P/B | 52.9 | · | 51.1 | 65.3 | 76.5 | · | 154.2 | 254.9 | 445.4 | · | 505.8 | 398.8 | 161.4 | · | |
| P / Tangible Book | 52.9 | · | 51.1 | 65.3 | 76.5 | · | 154.2 | 254.9 | 445.4 | · | 505.8 | 398.8 | · | · | |
| P / Cash Flow | -205.9 | · | · | · | -1180.1 | · | · | · | -19003.2 | · | · | · | -527.8 | · | |
| P / FCF | -205.9 | · | · | · | -1175.7 | · | · | · | -18959.2 | · | · | · | -522.8 | · | |
| Earnings Yield | 1.9% | · | 0.97% | 0.51% | · | · | · | · | · | · | · | · | · | · |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | |
|---|---|---|---|---|---|
| Utile netto | $-28M | $-12M | $-6M | $-27M | $-14M |
| EPS Diluito | $0.12 | $0.06 | — | — | — |
Stato Patrimoniale
| 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | |
|---|---|---|---|---|---|
| Rapporto corrente | 6.2 | 23.7 | 2.4 | 4.4 | — |
| Quick Ratio | 2.0 | 5.7 | 2.1 | 4.4 | — |
Flusso di cassa
| 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $-20M | $-13M | $-13M | $-17M | — |
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 13 filer · $615K totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 1 (-3 vs trimestre precedente) | 3 (0 vs trimestre precedente) | 4 (-2 vs trimestre precedente) | 4 (+1 vs trimestre precedente) | +28K |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | $154.404 | 95.311 | 25,09% | Azioni |
| ADAR1 Capital Management, LLC | $129.600 | 80.000 | 21,06% | Azioni |
| KESTRA PRIVATE WEALTH SERVICES, LLC | $99.970 | 61.710 | 16,25% | Azioni |
| Ikarian Capital, LLC | $83.904 | 51.793 | 13,64% | Azioni |
| RHUMBLINE ADVISERS | $49.457 | 30.529 | 8,04% | Azioni |
| XTX Topco Ltd | $25.899 | 15.987 | 4,21% | Azioni |
| Philadelphia Investment Partners, LLC | $24.300 | 15.000 | 3,95% | Azioni |
| Lido Advisors, LLC | $23.232 | 14.341 | 3,78% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $11.024 | 6.805 | 1,79% | Azioni |
| GAMMA Investing LLC | $7.679 | 4.740 | 1,25% | Azioni |
| MORGAN STANLEY | $5.792 | 3.575 | 0,94% | Azioni |
| SBI Securities Co., Ltd. | $55 | 34 | 0,01% | Azioni |
| Caitong International Asset Management Co., Ltd | $13 | 8 | 0,00% | Azioni |
Insider aziendali 13 insider · 4 dirigenti · 10 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Dale R Pfost | Chief Executive Officer | 25 Ottobre 2021 A | 2.500 | 0 | 0 | $0 |
| Sigal Fatal | Chief Financial Officer | 11 Novembre 2021 A | — | 0 | 0 | $0 |
| Donald Marvin | Executive VP, CFO & COO | 08 Novembre 2021 A | 2.000 | 0 | 0 | $0 |
| George Adi Mor | Chief Scientific Officer | 28 Ottobre 2016 A | 251.147 | 0 | 0 | $0 |
| Claude Nicaise | Direttore | 16 Marzo 2023 A | — | 0 | 0 | $0 |
| Jill M. Quigley | Direttore | 16 Giugno 2022 A | — | 0 | 0 | $0 |
| Joel Michael Maryles | Direttore | 19 Aprile 2021 A | 1.433 | 0 | 0 | $0 |
| Alan Charles Moses | Direttore | 19 Aprile 2021 A | — | 0 | 0 | $0 |
| Stephen P Squinto | Direttore | 19 Aprile 2021 A | — | 0 | 0 | $0 |
| Neil Harris Cohen | Direttore | 16 Marzo 2021 A | 10.000 | 0 | 0 | $0 |
| Stanislav Polovets | Direttore | 16 Luglio 2020 A | — | 0 | 0 | $0 |
| Nissim Darvish | Direttore | 28 Ottobre 2016 A | 1.200 | 0 | 0 | $0 |
| Peter Thiel | Proprietario del 10% | 16 Marzo 2021 P | 1.108.509 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 8 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| HBM Healthcare Investments (Cayman) Ltd. | 16 Luglio 2026 | 12,50% | Deposito iniziale | M&A / vendita | SEC |
| ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP, ORBIMED ISRAEL GP LTD., CHIMOVITS EREZ, GORDON CARL L ×6 depositi | 23 Giugno 2025 | 4,80% | Modifica | — | SEC |
| Adi Mor, Kobi George ×3 depositi | 29 Novembre 2024 | — | Deposito iniziale | — | SEC |
| Access Industries Holdings LLC, Access Industries, LLC, Access Industries Management, LLC, Clal Biotechnology Industries Ltd., Len Blavatnik ×6 depositi | 15 Aprile 2021 | — | Deposito iniziale | M&A / vendita | SEC |
| Palisade Medical Equity I, LP (2), Dennison T. Veru (2) ×2 depositi | 18 Dicembre 2020 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 27 Giugno 2019 | — | Deposito iniziale | — | SEC |
| Palisade Medical Equity I, LP, Dennison T. Veru | 25 Febbraio 2019 | — | Deposito iniziale | — | SEC |
| Clal Biotechnology Industries Ltd. 2), Clal Industries and Investments Ltd. 2) ×3 depositi | 08 Gennaio 2013 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.